ML researcher David Grangier joins Genesis to work on AI drug discovery
edunov · x · 2026-10-23
Machine learning researcher David Grangier announced he joined Genesis (@genesismolai) to work on AI for drug discovery, citing it as an impactful place to apply his expertise with plenty of exciting problems and room to explore ML methods. Colleague edunov welcomed him, noting exciting problems ahead.
More from Companies & People
- After data and compute, the next picks-and-shovels are talent and physical infrastructure — philhchen · 2026-10-23
- Critics slam Anthropic for rarely defending its work against criticism on Twitter — DKokotajlo · 2026-10-23
- Amazon blocks AI shopping agents while Walmart opens its site to them with spend controls — venturetwins · 2026-10-23
- Commenters speculate Skydance could wire Grok into its entire Hollywood production pipeline — MickeySteamboat · 2026-10-23
- Anthropic, OpenAI and Musk pledge over 3x the Gates Foundation, each with a different model — rohanpaul_ai · 2026-10-23
- CU Boulder's ATLAS Institute Opens Tenure-Track Robotics Professorship — ryosuzk · 2026-10-23